Targeting NETosis with PAD4 inhibitors offers promising results in inflammatory and thrombotic diseases, but carries a significant risk of off-target immune suppression due to disruption of dendritic cell and T-cell function. The gene discussed is PADI4; the disease is thrombotic disease.